As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Biolife Solutions Inc. The largest reported stake is BlackRock, Inc.'s, at 13.4%. 14 filings are on record since August 13, 2025 (Schedule 13G/A, October 27, 2026).
Sell to companies like Biolife Solutions Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 6,461,043 · Shared voting: 0 · Sole dispositive: 6,577,306 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Glazer Capital, LLC · Sole voting: 0 · Shared voting: 2,685,520 · Sole dispositive: 0 · Shared dispositive: 2,685,520 · SCHEDULE 13G, 2026-09-24
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 3,665,965 · Shared voting: 0 · Sole dispositive: 3,665,965 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-08
- · Holder: Casdin Capital, LLC · Percent: 9.7% · Shares: 4,757,165 · SCHEDULE 13G
- · Holder: Casdin Capital, LLC · Percent: 9.7% · SCHEDULE 13D/A
Biolife Solutions Inc has 14 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 13.4% | 6,577,306 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| Casdin Capital, LLC | 9.7% | 4,757,165 | SCHEDULE 13G, 2026-06-04 | 2026-06-04 |
| T. Rowe Price Investment Management, Inc. | 7.5% | 3,665,965 | SCHEDULE 13G/A, 2026-09-08 | 2026-08-31 |
| Glazer Capital, LLC | 5.49% | 2,685,520 | SCHEDULE 13G, 2026-09-24 | 2026-09-17 |
| Invesco Ltd. | 4.9% | 2,348,532 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Biolife Solutions Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Biolife Solutions Inc and the records around it.
Biolife Solutions Inc elsewhere on the record
Companies that share a holder
- Casdin Capital, LLC also filed stake reports on 3 other companies: Standard BioTools Inc. (Jun 2026), Relay Therapeutics, Inc. (Feb 2026), Codexis, Inc. (Nov 2025)
- Invesco Ltd. also filed stake reports on 83 other companies: Alignment Healthcare Inc (Aug 2026), ArcBest Corp (Aug 2026), ARKO Petroleum Corp (Aug 2026)
- Glazer Capital, LLC also filed stake reports on 107 other companies: Bumble Inc (Oct 2026), Weave Communications Inc (Oct 2026), Utz Brands Inc (Oct 2026)
Watch Biolife Solutions Inc
Get an email when Biolife Solutions Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biolife Solutions Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Biolife Solutions Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biolife Solutions Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,461,043 | 0 | 6,577,306 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Casdin Capital, LLC | 0 | 4,757,165 | 0 | 4,757,165 | SCHEDULE 13G, 2026-06-04 |
| Casdin Partners Master Fund, L.P. | 0 | 4,757,165 | 0 | 4,757,165 | SCHEDULE 13G, 2026-06-04 |
| Casdin Partners GP, LLC | 0 | 4,757,165 | 0 | 4,757,165 | SCHEDULE 13G, 2026-06-04 |
| Eli Casdin | 0 | 4,757,165 | 0 | 4,757,165 | SCHEDULE 13G, 2026-06-04 |
| T. Rowe Price Investment Management, Inc. | 3,665,965 | 0 | 3,665,965 | 0 | SCHEDULE 13G/A, 2026-09-08 |
| Glazer Capital, LLC | 0 | 2,685,520 | 0 | 2,685,520 | SCHEDULE 13G, 2026-09-24 |
| Paul J. Glazer | 0 | 2,685,520 | 0 | 2,685,520 | SCHEDULE 13G, 2026-09-24 |
The latest filing identifies Biolife Solutions Inc by CUSIP 09062W204 and gives its principal executive office as 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA 98021 (SCHEDULE 13G/A, 2026-10-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Casdin Capital, LLC | 15% | SCHEDULE 13D/A |
| 2025-08-14 | T. Rowe Price Investment Management, Inc. | 8.9% | SCHEDULE 13G |
| 2025-08-21 | Casdin Capital, LLC | 14% | SCHEDULE 13D/A |
| 2025-10-17 | Casdin Capital, LLC | 12.4% | SCHEDULE 13D/A |
| 2026-01-08 | T. Rowe Price Investment Management, Inc. | 10.8% | SCHEDULE 13G/A |
| 2026-02-12 | Invesco Ltd. | 8.2% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Invesco Ltd. | 4.9% | SCHEDULE 13G/A |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 13.5% | SCHEDULE 13G/A |
| 2026-05-22 | Casdin Capital, LLC | 9.7% | SCHEDULE 13D/A |
| 2026-06-04 | Casdin Capital, LLC | 9.7% | SCHEDULE 13G |
| 2026-09-08 | T. Rowe Price Investment Management, Inc. | 7.5% | SCHEDULE 13G/A |
| 2026-09-24 | Glazer Capital, LLC | 5.49% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 13.4% | SCHEDULE 13G/A |
Questions about who owns Biolife Solutions Inc
Who owns Biolife Solutions Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Biolife Solutions Inc: BlackRock, Inc. (13.4%, Schedule 13G/A, filed 2026-10-27), Casdin Capital, LLC (9.7%, Schedule 13G, filed 2026-06-04), T. Rowe Price Investment Management, Inc. (7.5%, Schedule 13G/A, filed 2026-09-08) and Glazer Capital, LLC (5.49%, Schedule 13G, filed 2026-09-24).
Who are the largest shareholders of Biolife Solutions Inc?
By the share each holder's latest filing reports, the largest holders of Biolife Solutions Inc on this page are BlackRock, Inc. (13.4%), Casdin Capital, LLC (9.7%) and T. Rowe Price Investment Management, Inc. (7.5%).
When did BlackRock, Inc. buy into Biolife Solutions Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-10-27, reporting 13.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Biolife Solutions Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 6, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Biolife Solutions Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.